Needham & Company Reiterates 'Buy' on Optimer Pharmaceuticals (OPTR); Collaborator/Competitor Cubist Confirms Plans to Bring CB-315 into Phase 3

Needham & Company reiterates a 'Buy' on Optimer Pharmaceuticals (NASDAQ: OPTR) price target of $19.00.

Needham analyst says, "Cubist (Nasdaq: CBST) announced this morning that the company plans to bring CB-315 forward into Phase 3 trials for the treatment of C. difficile infection. The company had previously indicated that it would likely do so and had begun manufacturing clinical trial supplies. A Phase 2 trial completed earlier this year demonstrated that the compound has a similar efficacy profile to that of Dificid. Without meaningful differentiation, we do not expect a substantial competitive threat for Optimer. We believe Cubist may launch the compound in 2015 or 2016, well after we expect Dificid to be established in the market."

For more ratings news on Optimer Pharmaceuticals click here and for the rating history of Optimer Pharmaceuticals click here.

Shares of Optimer Pharmaceuticals closed at $14.35 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Coherent (COHR) PT Raised to $420 at Needham
• Fiserv (FISV) PT Lowered to $60 at Freedom Broker
• Needham Reiterates Hold Rating on CoreWeave (CRWV)